The Ambry CARE Program® brings accurate, personalized breast cancer risk assessments directly into clinical workflows helping direct patients at high risk for breast cancer to seek additional ...

Clairity – developer of Clairity Breast, the first and only FDA-authorized offering to estimate a woman’s five-year breast cancer risk directly from a routine mammogram For the first time, clinicians ...

“Together with Genome Medical, we’re expanding access to genetic information and simplifying the integration of genetic services into providers’ practices,” said Moran Snir, Cofounder and CEO of Nest ...

For the first time, clinicians and patients will have access to an integrated view of genotype (Myriad’s MyRisk with RiskScore test) and phenotype (Clairity Breast) through MagView’s Luminary Risk ...